The York Suburban boys’ wrestling team was largely inexperienced last season. The Trojans went just 2-5 in dual meets and ...

Equity Insider News Commentary ? The oncology sector's pivot toward platform-based precision therapies has signaled smart money abandoning single-asset risk for companies engineering multiple drugs ...

The 2025 San Antonio Breast Cancer Symposium brought plenty of data and bold new ideas to the thousands of clinicians, ...

China’s focus on first or best-in-class oncology drugs and innovative R&D will position it well in 2026 and beyond.

Analysts are intrested in these 5 stocks: ( ($CWAN) ), ( ($HTBK) ), ( ($OVID) ), ( ($MCFT) ) and ( ($WHWK) ). Here is a breakdown of their recent ...

Detailed price information for Sutro Biopharma Inc (STRO-Q) from The Globe and Mail including charting and trades.

Innovation is accelerating through bispecifics and dual payload strategies | Emerging ADC development approaches such as ...

WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI ...

Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRRC15-targeting antibody-drug conjugateSIM0613 is optimally designed ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician ...